Comparative Pharmacology
Head-to-head clinical analysis: NEO FRADIN versus XIFAXAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEO FRADIN versus XIFAXAN.
NEO-FRADIN vs XIFAXAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Neomycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting bacterial protein synthesis. It also disrupts bacterial cell membrane integrity.
Rifaximin is a non-systemic, gut-selective antibiotic that inhibits bacterial RNA synthesis by binding to the beta-subunit of bacterial DNA-dependent RNA polymerase, thereby reducing bacterial overgrowth and altering gut microbiota composition.
50-100 mg/kg/day orally in 3-4 divided doses. Maximum 3 g/day.
550 mg orally twice daily for traveler's diarrhea; 550 mg orally three times daily for hepatic encephalopathy.
None Documented
None Documented
2-3 hours in normal renal function; prolonged to 24-30 hours in anuria or severe renal impairment; no significant change in hepatic disease.
The terminal elimination half-life for rifaximin after oral administration ranges from 1.8 to 10 hours, with a mean of approximately 6 hours. The half-life is extended in hepatic impairment due to reduced clearance, and no dosage adjustment is recommended for renal impairment.
Renal: >90% unchanged drug via glomerular filtration, with small amount reabsorbed; biliary/fecal: <2%.
Rifaximin is primarily eliminated unchanged in feces via biliary excretion (approximately 97% of an oral dose). Renal excretion of unchanged drug accounts for <0.4% of the dose. Fecal elimination is the major route.
Category C
Category C
Antibiotic
Antibiotic